about
Laser ablation for small hepatocellular carcinoma.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial.Laser ablation for small hepatocellular carcinoma: State of the art and future perspectivesIntermediate hepatocellular carcinoma: How to choose the best treatment modality?A rare cause of diuretic refractory ascites.Natural history of chronic hepatitis C virus infection.Refining sorafenib therapy: lessons from clinical practice.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.A prognostic index for patients within the intermediate stage of hepatocellular carcinoma.Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in hepatocellular carcinoma patients.The impact of previous or concomitant IFN therapy on deferiprone-induced agranulocytosis and neutropenia: a retrospective study.Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation.Hepatitis C virus distribution and clearance following interferon-monotherapy among thalassaemia major and intermedia patients.Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study.Incidence of side effects during therapy with different types of alpha interferon: a randomised controlled trial comparing recombinant alpha 2b versus leukocyte interferon in the therapy of naive patients with chronic hepatitis C.Three cases of severe acute hepatitis after parenteral administration of amiodarone: the active ingredient is not the only agent responsible for hepatotoxicity.[Prevalence of antibody to hepatitis C virus in hospital personnel]Prospective analysis of risk factors for hepatocellular carcinoma on patients with cirrhosis.Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.Fatal ischemic acute pancreatitis complicating trans-catheter arterial embolization of small hepatocellular carcinoma: do the risks outweigh the benefits?Acute rejection after liver transplantation: Is there a specific immunological pattern?Prevalence of anti-HCV among spouses and offspring of anti-HCV positive subjects: an Italian multicentre study.Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation.Effect of alcohol, cigarette smoking, and diabetes on occurrence of hepatocellular carcinoma in patients with transfusion-acquired hepatitis C virus infection who develop cirrhosis.Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis.Prognostic value of quantitative liver function tests in viral cirrhosis: a prospective study.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Hepatic splenosis misinterpreted as hepatocellular carcinoma in cirrhotic patients referred for liver transplantation: report of two cases.Evidence of Liver Histological Alterations in Apparently Healthy Individuals Evaluated for Living Donor Liver TransplantationSurvival after locoregional treatments for hepatocellular carcinoma: a cohort study in real-world patientsRandomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis BAdjuvant therapy for interferon-resistant patients: do cyclooxygenase inhibitors have any role? A pilot studyResistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosisEfficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre studyFactors influencing outcome of lamivudine in anti-HBe-positive chronic hepatitis BSafety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practicePreserved liver function, portal thrombosis and absence of oesophageal varices are risk factors for metastasis of hepatocellular carcinoma
P50
Q34108430-A671B824-194D-4D77-97BA-8FEED4AC6CBBQ34109952-E0AE37E7-1F01-435B-B91C-4D74E67AFF24Q35273624-063033DE-27A6-4FDC-A66A-19691E6D8289Q35370564-CEE59749-0241-4C5F-8E47-0F13ADC6F4C4Q35626764-AA01612D-6099-4C97-9992-5095E5568C35Q35760841-AF380B64-9725-45FF-84BB-49C6F5854CD6Q36971062-98DC8BF1-C077-4F8C-9675-D9D670080407Q38264146-B2CAA4EE-538C-4B9E-8C3F-75AF07A08780Q39030388-FD984C9F-D06F-4412-B621-3099C34F52E6Q39510564-E7B36ED4-A87F-4485-919C-D5C6B1FCA9A6Q39922574-A7F2A947-ACBE-425D-9EA1-8A4D3635F3ECQ42510932-4E14F835-B44C-4747-896A-A96DC844D8B5Q42859202-728C5BB1-3AB8-4FFE-A932-74BE1432B59EQ42992027-81661D76-3F93-4004-94E8-27A358580ECEQ43034823-87842CFC-255F-47C4-B545-9F906C9FDA34Q43036715-36682727-63F9-45BF-948C-A5AB3BFAB952Q43756998-7095CD8C-C122-4FB1-867B-1515634C2882Q43955378-D59FE52F-AB84-4DE7-8C5C-AC420B993A01Q44196036-D56A1990-902F-4216-B882-08CB265FD273Q44273116-6D25C2A7-1B7D-4F72-B00E-182E0BD6D8DEQ44598602-8392964B-F71D-4D18-AC1C-A7ABBD4A0228Q44833504-742C4948-0D4E-451B-B516-2993000102CEQ44885943-C179D132-5041-4EDA-AA75-FD954550F16FQ45225073-28A08470-D65B-479C-AE7B-065F2DDDB61DQ45279719-BF99CDB2-EE53-4A32-B25F-791AF582FCEFQ45383425-78F92535-B21F-468F-ABE6-5FA6BAE01C46Q45392334-73D2E846-D1B3-4623-832B-29D29265ED12Q46476300-52300E54-743F-4146-A10F-1706987471C8Q48691054-50C9EDC0-1754-4094-BBF0-3143C91A795CQ50512896-B9721F6C-335D-4C09-87AE-B78009D906A0Q53624770-BAA5AFAB-FC28-4E1B-A6A0-67ED51ECB803Q58832270-BE0A06B2-737C-480F-9C10-A1723976FB38Q58914838-1ACF2013-FECD-4EC9-A751-82B89B1A040AQ61054082-B8A0E38D-63DD-4520-A1AB-43373FC5FE12Q70872014-45C0DD53-20DD-475E-BDDA-D8EEA2B04FA2Q71493071-5C3BE4B1-4FEC-4AF8-8A71-1DDA801398BCQ77626895-AFCA0A1C-9674-4713-B2C0-3259CE50EE4AQ79414754-7C6D8840-170B-4679-A2D7-80E3981F498CQ84115386-8D2E4CCA-61B5-49DD-AD63-068AB5AD5B26Q85206200-612ABC11-E8B0-4503-9BAE-C2D4252A239E
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giovan G Di Costanzo
@ast
Giovan G Di Costanzo
@en
Giovan G Di Costanzo
@es
Giovan G Di Costanzo
@nl
Giovan G Di Costanzo
@sl
type
label
Giovan G Di Costanzo
@ast
Giovan G Di Costanzo
@en
Giovan G Di Costanzo
@es
Giovan G Di Costanzo
@nl
Giovan G Di Costanzo
@sl
prefLabel
Giovan G Di Costanzo
@ast
Giovan G Di Costanzo
@en
Giovan G Di Costanzo
@es
Giovan G Di Costanzo
@nl
Giovan G Di Costanzo
@sl
P106
P21
P31
P496
0000-0002-8996-0256